HAYWARD,
Calif., April 15, 2024 /PRNewswire/
-- Avirmax Inc., will make two scientific presentations at the
upcoming American Society of Gene and Cell Therapy (ASGCT) annual
meeting in Baltimore between
May 7th and
11th, 2024. In addition, Avirmax will have an exhibitor
booth #818 to showcase the latest progress and data package. ASGCT
is the largest international society dedicated to understanding,
development, and application of gene and cell therapy.
Title: Macular retina-targeting AAV capsid identified through
multi-species screening in mice, rabbits, pigs, and
monkeys
Presenter: Li Ou,
Ph.D.
Session title: AAV Capsid Engineering: Multilevel Approaches for
Enhanced AAV Delivery
Presentation type: Oral Presentation
Date and Time: Friday, May 10,
3:45pm - 4:00pm
This presentation focuses on Avirmax's lead candidate ABI-110
for wet AMD and PCV using a proprietary novel capsid AAV2.N54.
AAV2.N54 was developed through capsid engineering and showed
significantly improved tropism to the macular retina over wildtype
serotypes and AAV2.7m8 in mice, rabbits, pigs, and non-human
primates. Avirmax Biopharma has completed cGMP manufacturing of
ABI-110 using VSafTM rAAV Production Platform with
Sf-rhabdovirus free Sf9 cells and presently prepares regulatory
submission for clinical investigations.
Title: Comprehensive Head-to-Head Comparisons Demonstrated
Key Advantages of The Sf9 System Over HEK293 in rAAV
Manufacturing
Presenter: Li
Ou, Ph.D.
Session title: AAV Vectors - Product Development Manufacturing and
Approval Considerations
Presentation type: Poster Presentation
Date and Time: Friday, May 10,
12:00 pm
This presentation focuses on the systematic comparison between
AAV vectors manufactured by the traditional HEK293 plasmid
transfection system and the Sf9/baculoviral infection system. As
shown in the publication in Molecular Therapy from Avirmax, the Sf9
system has advantages in yields, full capsid ratio, aggregation,
purity, and potency over traditional HEK293 systems.
About Avirmax Inc.
Avirmax Inc. is a San
Francisco-based company specializing in developing
rAAV-mediated therapeutics for ocular diseases using its AAV
engineering technologies and Sf9-based AAV manufacturing platform.
Visit us at avirmax.com for more information.
References
Liu S, Li J, Peraramelli S, Luo N, Chen A, Dai M, Liu F, Yu Y,
Leib RD, Li Y, Lin K, Huynh D, Li S, Ou L. Systematic comparison of
rAAV vectors manufactured using large-scale suspension cultures of
Sf9 and HEK293 cells. Mol Ther. 2023 Nov
20:S1525-0016(23)00623-8.
Contact
Please contact
June Song, Associate Director for
Operations
Email: business@avirmax.com
Tel: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avirmax-inc-to-make-scientific-presentations-at-asgct-in-baltimore-302117506.html
SOURCE Avirmax